Completion of patient dosing in Phase 2b clinical trial
Filed with ASX · · 3 pages · English
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Completion of enrolment in Phase 2b arm
- ISLA-101 Phase 2b clinical trial enrols first subjects
- US patent granted for ISLA-101
- ISLA-101 shows anti-dengue activity in Phase 2a readout
- Receipt of R&D tax refund for FY2024
Later from Island Pharmaceuticals
- Phase 2a/b clinical trial update
- Quarterly Activities & Cashflow Report
- Island completes $3.6 million placement
- Successful Phase 2 clinical trial of ISLA-101
- Portfolio expansion achieved with acquisition of Galidesivir
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals